MARGINAL ZONE LYMPHOMA

This study is testing whether a new two-drug combination (Mosunetuzumab and Lenalidomide) works better than current standard treatments for people with a specific type of lymphoma that has come back or stopped responding to prior therapy. It will involve about 260 adults whose ca…

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug moves through the body. Researchers will als…

This early-phase trial is testing a combination treatment for adults with B-cell lymphomas that have come back or stopped responding to standard therapies. The approach involves giving patients a daily oral drug (pirtobrutinib) before and after an infusion of their own geneticall…

This study is testing an investigational drug called epcoritamab in adults who have just been diagnosed with marginal zone lymphoma (MZL) and have not yet received any treatment. The main goal is to see how many participants achieve a complete response, meaning no detectable canc…

This study is testing a new type of treatment called EO2463, which is a therapeutic vaccine designed to teach the body's immune system to recognize and attack lymphoma cells. It will be given to patients with slow-growing non-Hodgkin's lymphoma, both by itself and in combination …

This study is testing a new type of cell therapy called CTX112 for people with B-cell blood cancers that have come back or not responded to other treatments. Doctors use CRISPR gene-editing technology to modify donor immune cells to better target and fight the cancer. The main go…

This study is testing whether a new drug combination (zanubrutinib plus an antibody) works better than the current standard treatment (lenalidomide plus rituximab) for people whose follicular or marginal zone lymphoma has returned or stopped responding to prior therapy. It will e…

This study is testing whether combining two drugs—mosunetuzumab and lenalidomide—works better than current treatments for people newly diagnosed with certain slow-growing lymphomas. The trial will enroll 52 adults who haven't had any previous cancer treatment. Doctors will adjust…

This is a first-in-human study testing a new type of personalized immune cell therapy (CAR-T cells) for adults with Non-Hodgkin Lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe dose of these modified immune cells, which are…

This study aims to understand how the drug zanubrutinib works for adults with certain blood cancers in everyday clinic settings, not a controlled trial. It will follow about 705 patients to see how the treatment affects their quality of life, how often they need hospital care, an…

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing whether a very low dose of radiation therapy works as well as the standard, higher dose for people with early-stage, slow-growing B-cell lymphomas. Researchers want to see if the lower dose can control the cancer just as effectively while causing fewer side …

This study is testing whether adding a newer drug called orelabrutinib to standard treatments works better for people newly diagnosed with marginal zone lymphoma, a type of blood cancer. It has two groups: one for younger, fitter patients and one for older patients or those less …

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This study is testing whether a new oral drug, pirtobrutinib, works well when combined with the standard drug rituximab for adults newly diagnosed with marginal zone lymphoma, a type of slow-growing blood cancer. The main goal is to see how many patients' cancer shrinks or disapp…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing if a combination of two drugs, rituximab and venetoclax, can effectively treat marginal zone lymphoma (MZL) in people who haven't had chemotherapy before. The goal is to control the cancer and keep it from coming back. About 33 participants will receive the …

This study aims to understand and better manage high blood pressure and heart risks in people with certain blood cancers who are taking a specific type of medication called a BTK inhibitor. Researchers will closely monitor 100 patients for one year to see how often these side eff…

This study is testing a two-drug combination (acalabrutinib and obinutuzumab) for people with untreated, slow-growing non-Hodgkin lymphomas. The goal is to see if this approach can effectively control the cancer, improve quality of life, and determine if patients who achieve a co…

This study is testing whether combining two existing drugs—rituximab and zanubrutinib—is safe and effective for people with untreated slow-growing B-cell lymphomas. It will enroll 43 adults with either follicular lymphoma or marginal zone lymphoma who need systemic treatment. Res…

This study is testing a new oral medication called AS-1763 for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The trial will enroll a…

This study is testing an experimental drug called loncastuximab tesirine in adults whose marginal zone lymphoma has returned or stopped responding to standard treatments. Researchers want to see if the drug can shrink or eliminate tumors and how safe it is for patients. The study…

This study is testing whether an oral drug called pemigatinib can help control two specific types of B-cell non-Hodgkin lymphoma that have come back or stopped responding to standard treatments. It is for adults with mantle cell lymphoma or marginal zone lymphoma who have already…

This study is testing whether a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—is safe and effective for people whose follicular or marginal zone lymphoma has come back or hasn't responded to prior treatments. About 45 participants will receive the treatment …

This is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…

This study is observing how well and how safely a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma. It will follow 30 patients who have not had prior systematic treatment for their cancer. The main goal is t…

This study aims to learn more about marginal zone lymphoma, a type of blood cancer, by tracking 2,500 newly diagnosed patients over time. Researchers will observe how the disease behaves and how well different treatments work, without testing new drugs. The goal is to gather real…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …